Date Published
November 2014

Page Count 
164

Additional Info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

 

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 



Vaccines: The End of Illness Overview

New to Insight Pharma Reports is Vaccines: The End of Illness. This report focuses on the most recent vaccine research, emphasizing their reputation as an unmatched tool of efficient healthcare. Their low cost, extended protection and the impossibility of their circumvention through development of resistance on the part of the target pathogen have been longstanding attributes of vaccines. Today, vaccine technology is undergoing a fundamental revolution, taking advantage of the profound understanding of the immune system and its ability to mount protective antibody production and cell-based responses to foreign antigens. Understanding these properties will not only enable the development of innovative diagnostics but also the advancement of therapeutic applications.

Specific Highlights Include:

  • This report profiles some of the major pharma companies involved in vaccine R&D and a number of biotech companies developing new vaccine products and technologies – including 35 small pharma companies and 8 big pharma companies profiled
  • The logistics and management of the vaccine industry are increasingly based on partnerships between the private sector (pharma and biotech companies), government agencies (WHO) and large non-profits (such as the Gates Foundation).
  • An assessment of the future directions of vaccines as innovative medical therapies for a wide range of diseases.
  • Explores conditions not normally thought to be in purview of vaccination, including substance abuse and neurological disorders such as Alzheimer’s disease and Parkinson’s disease.
  • Survey of industry experts concerning the political economic and technological future of vaccine technology.
  • Over 20 pages of pipeline and clinical trial data specific to vaccine targets
  • Over 30 pages of pipeline and clinical trial data specific to cancer vaccines